Eosinophilic esophagitis - Diagnosis and treatment - Mayo Clinic Monoclonal antibodies The Food and Drug Administration (FDA) recently approved dupilumab (Dupixent) for treatment of adults and children 12 years and older with eosinophilic esophagitis Dupilumab is a type of medicine known as a monoclonal antibody It works to block the action of certain proteins in the body that cause inflammation
DUPIXENT® (dupilumab) For Eosinophilic Esophagitis Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb (15kg) Serious side effects can occur Please see Important Safety Information and Prescribing Information and Patient Information on website